HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma

被引：0
|
作者：
Zimin Liu
Mingpeng Shi
Xiaoxiao Li
Shanai Song
Ning Liu
Haiwei Du
Junyi Ye
Haiyan Li
Zhou Zhang
Lu Zhang
机构：
[1] The Affiliated Hospital of Qingdao University,Oncology Department
[2] Burning Rock Biotech,Operating Room of Neurosurgery
[3] The Affiliated Hospital of Qingdao University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Copy number; Resectable gastric adenocarcinoma; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1315 / 1324
页数：9
相关论文
共 50 条
  • [31] Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio < 2, HER2 copy number ≥ 6): Are they mostly HER2 "positive?"
    Wei, Christina H.
    Yang, Lixin
    Stewart, Daphne
    Bedell, Victoria
    Schmolze, Daniel
    Apple, Sophia
    Murata-Collins, Joyce L.
    Pillai, Raju
    Mortimer, Joanne E.
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
    Wakatsuki, Takeru
    Yamamoto, Noriko
    Sano, Takeshi
    Chin, Keisho
    Kawachi, Hiroshi
    Takahari, Daisuke
    Ogura, Mariko
    Ichimura, Takashi
    Nakayama, Izuma
    Osumi, Hiroki
    Matsushima, Tomohiro
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Hiki, Naoki
    Ishikawa, Yuichi
    Yamaguchi, Kensei
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (11) : 1186 - 1195
  • [33] Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
    Takeru Wakatsuki
    Noriko Yamamoto
    Takeshi Sano
    Keisho Chin
    Hiroshi Kawachi
    Daisuke Takahari
    Mariko Ogura
    Takashi Ichimura
    Izuma Nakayama
    Hiroki Osumi
    Tomohiro Matsushima
    Mitsukuni Suenaga
    Eiji Shinozaki
    Naoki Hiki
    Yuichi Ishikawa
    Kensei Yamaguchi
    Journal of Gastroenterology, 2018, 53 : 1186 - 1195
  • [34] Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.
    Ran, Ran
    Huang, Wenfa
    Lin, Shao
    Niu, Yunyun
    Rugo, Hope S.
    Kong, Weiyao
    Bo, Shiping
    Lu, Sijia
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [36] Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
    Wang, Kang
    Zhu, Yajing
    Zerdes, Ioannis
    Sifakis, Emmanouil
    Manikis, Georgios
    Salgkamis, Dimitrios
    Tsiknakis, Nikolaos
    Harbers, Luuk
    Crosetto, Nicola
    Bergh, Jonas
    Matikas, Alexios
    Hatschek, Thomas
    Foukakis, Theodoros
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [38] Treating HER2-positive disease
    Brain, Etienne
    FUTURE ONCOLOGY, 2017, 13 (08) : 11 - 11
  • [39] HER2/neu as target in gastric adenocarcinoma
    Cetin, Bulent
    Ozet, Ahmet
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 1
  • [40] Biomarkers in Her2-Positive Disease
    Klocker, Eva Valentina
    Suppan, Christoph
    BREAST CARE, 2020, 15 (06) : 586 - 593
12345